Skip to Main Content

Paper Details

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Blood
14
2022
Author NameAffiliation
Felicia GomezDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Felicia GomezMcDonnell Genome Institute, Washington University School of Medicine
Kilannin KrysiakDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Kilannin KrysiakMcDonnell Genome Institute, Washington University School of Medicine
Kilannin KrysiakWashington University School of Medicine
Alina D SchmidtDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Alina D SchmidtMcDonnell Genome Institute, Washington University School of Medicine
Zachary L SkidmoreDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine
Malachi GriffithDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine
Obi L GriffithDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine
Todd A FehnigerDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
  • 1 - 14

Datasets